Autologous Human Schwann Cell Augmentation for Severe Peripheral Nerve Injury

Phase 1, open-label, single-arm trial of autologous human Schwann cells in peripheral nerve injury (PNI). Primary endpoints: Number of participants with reported adverse events at 12 months, Number of participants with reported cell product culture test failure at 12 months and 5 more. Started Sep 2019; status: completed.